title: An update on new and emerging options for the treatment of vitiligo.
abstract: Vitiligo is an acquired leukoderma that results from the loss of epidermal melanocytes, and is characterized by macules and patches of depigmented skin. With a relatively high rate of prevalence, vitiligo occurs in localized, generalized, or segmental patterns; it can run a rapidly progressive course or remain stationary. The pathogenesis of vitiligo is not yet fully understood, but the autoimmune hypothesis is the most commonly accepted one, based on which, many treatment modalities have been described. Although many therapeutic options exist and new modalities are still emerging, treatment challenges persist, as not all patients respond to available therapies. Variables that affect the choice of treatment include the extent, distribution, and progression rate of the lesions. Another challenge is the lack of a standardized scoring system, which hampers the production of level 1a evidence studies for the treatment of this condition.
authors: Department of Dermatology, Henry Ford Hospital, Detroit, MI, USA.
authors: B H
authors: BH
authors: Mahmoud
authors: C L
authors: CL
authors: Hexsel
authors: I H
authors: IH
authors: Hamzavi
mesh_terms: D000279:Administration, Cutaneous; D000305:Adrenal Cortex Hormones / Q000627:therapeutic use*; D002117:Calcitriol / Q000031:analogs & derivatives / Q000627:therapeutic use; D003131:Combined Modality Therapy; D003879:Dermatologic Agents / Q000627:therapeutic use*; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use*; D028022:Low-Level Light Therapy; D010789:Phototherapy; D016559:Tacrolimus / Q000627:therapeutic use; D014820:Vitiligo / Q000188:drug therapy / Q000532:radiotherapy / Q000601:surgery
chemical_list: D000305:Adrenal Cortex Hormones; D003879:Dermatologic Agents; D007166:Immunosuppressive Agents; C055085:calcipotriene; D002117:Calcitriol; D016559:Tacrolimus